
|Articles|June 23, 2008
Stiefel Laboratories to acquire Barrier Therapeutics
Coral Gables, Fla. - Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
Advertisement
Coral Gables, Fla.
- Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
The transaction is valued at approximately $148 million, and is subject to valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















